Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | MGMT | P16455 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114184 | 0.74 | MAPT (0.46) | CYP1A2ATMCDK1CCNB1MGMT | |
| SCHEMBL2115403 | 0.71 | MAPK1 (0.47) | ATMCDK1CCNB1MGMTCCNA2 | |
| SCHEMBL4318852 | 0.71 | MAPT (0.47) | ATMCDK1CCNB1MGMTCCNA2 | |
| SCHEMBL6268748 | 0.68 | CDK1 (0.43) | ATMCDK1CCNB1MGMTCCNA2 | |
| SCHEMBL6268751 | 0.68 | CDK1 (0.69) | CDK1CCNB1MGMTCCNA2CDK2 | |
| SCHEMBL11143431 | 0.68 | MAPT (0.39) | ATMCDK1CCNB1MGMTCCNA2 | |
| SCHEMBL2440352 | 0.67 | ALDH1A1 (0.42) | ATMCDK1CCNB1MGMTCCNA2 | |
| SCHEMBL11017179 | 0.66 | CYP1A2 (0.80) | CYP1A2MAPT | |
| SCHEMBL27963414 | 0.64 | ATM (0.33) | ATMCDK1CCNB1MGMTCCNA2 | |
| SCHEMBL31074877 | 0.64 | MAPT (0.35) | ATMHIF1AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2436701-B2 | Method for storing triallyl isocyanurate | SHINRYO CORP (JP) | 2021-12-22 | — | — | EP | disclosed |
| CN-102449001-B | Method for storing triallyl isocyanurate | NIPPON KASEI CHEM | 2014-04-23 | — | — | CN | disclosed |
| EP-2436701-B1 | Method for storing triallyl isocyanurate | NIPPON KASEI CHEM (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-8431697-B2 | Triallyl isocyanurate, triallyl cyanurate and process for producing triallyl isocyanurate | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2013-04-30 | — | — | US | disclosed |
| CN-102449001-A | Method for storing triallyl isocyanurate | NIPPON KASEI CHEM | 2012-05-09 | — | — | CN | disclosed |
| CN-102438997-A | Triallyl isocyanurate, triallyl cyanurate, and process for producing triallyl isocyanurate | NIPPON KASEI CHEM | 2012-05-02 | — | — | CN | disclosed |
| US-20120095225-A1 | METHOD OF STORING TRIALLYL ISOCYANURATE | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095223-A1 | TRIALLYL ISOCYANURATE, TRIALLYL CYANURATE AND PROCESS FOR PRODUCING TRIALLYL ISOCYANURATE | NIPPON CHEMICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095225-A1 | METHOD OF STORING TRIALLYL ISOCYANURATE | TIMCC, TST, TMT1A | CYP1A2 2769/4885ATM 236/4885CDK1 484/4885 |
| US-20120095223-A1 | TRIALLYL ISOCYANURATE, TRIALLYL CYANURATE AND PROCESS FOR PRODUCING TRIALLYL ISOCYANURATE | CA9, CROCC, CA2 | CYP1A2 210/4885ATM 1245/4885CDK1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.